Drug Profile
SL 1112
Latest Information Update: 02 Apr 1997
Price :
$50
*
At a glance
- Originator Sanofi-Synthelabo
- Class Antiarrhythmics
- Mechanism of Action Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Arrhythmias
Most Recent Events
- 02 Apr 1997 No-Development-Reported for Arrhythmias in France (Unknown route)
- 24 Oct 1994 Preclinical development for Arrhythmias in France (Unknown route)